Fig. 8

CD73 expression as an indicator of response to Cetuximab in HNSCC. A CD73 mRNA expression was analyzed in Cetuximab non-responder and responder PDX-derived HNSCC models within the GSE84713 dataset as violin plots with single data points and median values. B Receiver operating characteristics of specificity and sensitivity of the CD73 expression to distinguish non-responder and responder PDXs following Cetuximab treatment in xenotransplantation models (AUC: area under the curve). C CD73 mRNA expression was analyzed in the Bossi et al. cohort [5] comprised of advanced, metastasized HNSCC patients treated with Cetuximab with either short progression-free survival (PFS; n = 26; PFS < 3 months) or long PFS (n = 14; PFS > 19 months). CD73 mRNA expression is shown for short and long PFS as violin plot with single data points and median values. D Receiver operating characteristics of specificity and sensitivity of the CD73 expression to distinguish short and long PFS (AUC: area under the curve). E Multivariate linear regression model for the capacity of CD73 expression and clinical parameters (age, gender, tumor grade, tumor stage, and radiotherapy) to estimate the odds for short or long PFS. All variables are indicated including each reference, odds ratio, patient numbers (N), 95% CI, and p-value. CD73 was stratified according to median expression